HRP20050872A2 - Use of carbamazepine derivatives for the treatment of agitation in dementia patients - Google Patents

Use of carbamazepine derivatives for the treatment of agitation in dementia patients

Info

Publication number
HRP20050872A2
HRP20050872A2 HR20050872A HRP20050872A HRP20050872A2 HR P20050872 A2 HRP20050872 A2 HR P20050872A2 HR 20050872 A HR20050872 A HR 20050872A HR P20050872 A HRP20050872 A HR P20050872A HR P20050872 A2 HRP20050872 A2 HR P20050872A2
Authority
HR
Croatia
Prior art keywords
agitation
treatment
dementia patients
compound
formula
Prior art date
Application number
HR20050872A
Other languages
English (en)
Croatian (hr)
Inventor
Shua-Haim Joshua
Martenyi Ferenc
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20050872A2 publication Critical patent/HRP20050872A2/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
HR20050872A 2003-04-01 2005-09-30 Use of carbamazepine derivatives for the treatment of agitation in dementia patients HRP20050872A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45933803P 2003-04-01 2003-04-01
PCT/EP2004/003418 WO2004087166A1 (en) 2003-04-01 2004-03-31 Use of carbamazepine derivatives for the treatment of agitation in dementia patients

Publications (1)

Publication Number Publication Date
HRP20050872A2 true HRP20050872A2 (en) 2006-12-31

Family

ID=33131880

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20050872A HRP20050872A2 (en) 2003-04-01 2005-09-30 Use of carbamazepine derivatives for the treatment of agitation in dementia patients

Country Status (25)

Country Link
US (2) US20070066593A1 (pt)
EP (1) EP1613328B8 (pt)
JP (1) JP2006522050A (pt)
KR (1) KR20050121236A (pt)
CN (1) CN1767833A (pt)
AT (1) ATE425756T1 (pt)
AU (1) AU2004226805B2 (pt)
BR (1) BRPI0408956A (pt)
CA (1) CA2521371A1 (pt)
DE (1) DE602004020060D1 (pt)
ES (1) ES2323270T3 (pt)
HK (1) HK1090543A1 (pt)
HR (1) HRP20050872A2 (pt)
IS (1) IS8096A (pt)
MA (1) MA27638A1 (pt)
MX (1) MXPA05010608A (pt)
NO (1) NO20054994L (pt)
NZ (1) NZ542554A (pt)
PL (1) PL1613328T3 (pt)
PT (1) PT1613328E (pt)
RU (1) RU2351338C2 (pt)
TN (1) TNSN05247A1 (pt)
TW (1) TW200501962A (pt)
WO (1) WO2004087166A1 (pt)
ZA (1) ZA200507439B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients
GB0424563D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
GB0517740D0 (en) * 2005-08-31 2005-10-12 Novartis Ag Organic compounds
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US20110251172A1 (en) * 2008-08-13 2011-10-13 Rivkin Alexey A Purine derivatives for treatment of alzheimer's disease
CN102180965B (zh) * 2011-03-02 2014-01-01 广州金域医学检验中心有限公司 卡马西平免疫原、抗卡马西平特异性抗体、检测试剂及检测试剂盒
CN102183659B (zh) * 2011-03-02 2014-07-02 广州金域医学检验中心有限公司 一种卡马西平检测方法
RU2504367C1 (ru) * 2012-06-05 2014-01-20 Государственное бюджетное образовательное учреждение высшего профессионального образования "Амурская государственная медицинская академия" Минздравсоцразвития Российской Федерации Способ коррекции психического состояния пациентов и антиоксидантного статуса при органическом расстройстве личности

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH500196A (de) * 1969-03-10 1970-12-15 Ciba Geigy Ag Verfahren zur Herstellung von neuen Azepinderivaten
US3637661A (en) * 1970-03-04 1972-01-25 Ciba Geigy Corp 10-hydroxy-10 11-dihydro-dibenzazepine derivative
US5827819A (en) * 1990-11-01 1998-10-27 Oregon Health Sciences University Covalent polar lipid conjugates with neurologically active compounds for targeting
JP3057471B2 (ja) * 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
PT101732B (pt) * 1995-06-30 1997-12-31 Portela & Ca Sa Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso
US5736647A (en) * 1995-08-07 1998-04-07 Oval Corporation Vortex flow meter detector and vortex flow meter
KR20010072878A (ko) * 1998-10-16 2001-07-31 디르크 반테 인식을 개선하기 위한 아세틸콜린에스테라제 억제제와배합된 비정형 항정신병제
CA2395695A1 (en) * 1999-12-30 2001-07-12 Proteotech, Inc. Catechins and green tea extract for the treatment of amyloidosis in alzheimer's disease and other amyloidoses
GB0113663D0 (en) * 2001-06-05 2001-07-25 Novartis Ag Use of organic compounds
TW200501962A (en) * 2003-04-01 2005-01-16 Novartis Ag Use of carbamazepine derivatives for the treatment of agitation in dementia patients

Also Published As

Publication number Publication date
ES2323270T3 (es) 2009-07-10
US20090192142A1 (en) 2009-07-30
PL1613328T3 (pl) 2009-08-31
CA2521371A1 (en) 2004-10-14
ZA200507439B (en) 2007-06-27
EP1613328B1 (en) 2009-03-18
EP1613328B8 (en) 2009-06-10
NO20054994L (no) 2005-10-26
TNSN05247A1 (en) 2007-06-11
ATE425756T1 (de) 2009-04-15
WO2004087166A1 (en) 2004-10-14
RU2351338C2 (ru) 2009-04-10
AU2004226805A1 (en) 2004-10-14
KR20050121236A (ko) 2005-12-26
BRPI0408956A (pt) 2006-04-04
EP1613328A1 (en) 2006-01-11
MA27638A1 (fr) 2005-11-01
CN1767833A (zh) 2006-05-03
PT1613328E (pt) 2009-06-15
JP2006522050A (ja) 2006-09-28
HK1090543A1 (en) 2006-12-29
IS8096A (is) 2005-10-27
TW200501962A (en) 2005-01-16
RU2005133478A (ru) 2007-06-10
DE602004020060D1 (de) 2009-04-30
MXPA05010608A (es) 2005-11-23
US20070066593A1 (en) 2007-03-22
AU2004226805B2 (en) 2008-03-06
NZ542554A (en) 2008-10-31

Similar Documents

Publication Publication Date Title
HK1090543A1 (en) Use of carbamazepine derivatives for the treatment of agitation in dementia patients
MY138352A (en) Benzothiazole derivatives
JO2371B1 (en) 4-phenyl-pyridine derivatives
MX2008001606A (es) Piperazinas substituidas como antagonistas de receptor de glutamato metabotropico.
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
BR0317600A (pt) ácidos heteroarilalcanóicos como derivados de antagonistas de receptor de integrina
UA90858C2 (ru) Композиция с контролируемым высвобождением варденафила
WO2006038006A3 (en) 5-sulfonyl-1-piperidinyl substituted indole derivatives as 5-ht6 receptor antagonists for the treatment of cns disorders
WO2003048164A3 (en) Adenosine a2a receptor antagonists
WO2007143523A8 (en) Fused, tricyclic sulfonamide inhibitors of gamma secretase
SG147450A1 (en) Sustained release pharmaceutical compositions comprising aplindore and derivatives thereof
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
PL1682528T3 (pl) Pochodne benzo[b][1,4]dioksepiny
UA84896C2 (ru) Производные гидронопола как агонисты человеческих рецепторов orl1
EP1784173A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC BONE DISEASES CONTAINING ALPHA-ARYLMETHOXYACRYLATE DERIVATIVES
NO20032261L (no) Medisinske preparater
MY133512A (en) Non-steroidal il-5 inhibitors, processes and intermediates for their preparation and pharmaceutical compositions comprising said inhibitors
TW200519101A (en) Benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
SE0002729D0 (sv) Novel compound form
MX2008001607A (es) Piperazinas biciclicas como antagonistas del receptor de glutamato metabotropico.
DE69917005D1 (de) Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung
TW200519102A (en) Hydronopol substituted benzimidazolone and quinazolinone derivatives as agonists on human ORL1 receptors
TW200607498A (en) Agents for prevention or treatment of diseases associated with endothelial hyperproliferation
NO20061966L (no) Bicyklo[3.1.1.]heptansubstituerte benzimidazolon- og kinazolinonderivater som agonister for humane ORL1 reseptorer

Legal Events

Date Code Title Description
A1OB Publication of a patent application
ARAI Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20090320

Year of fee payment: 6

OBST Application withdrawn